Context Therapeutics (CNTX) Projected to Post Earnings on Thursday

Context Therapeutics (NASDAQ:CNTX) is projected to announce its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Context Therapeutics to post earnings of ($0.10) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Context Therapeutics Trading Up 8.6%

Context Therapeutics stock opened at $3.17 on Thursday. The business’s 50 day simple moving average is $2.15 and its 200 day simple moving average is $1.46. Context Therapeutics has a 12 month low of $0.49 and a 12 month high of $3.30. The company has a market cap of $291.26 million, a price-to-earnings ratio of -13.21 and a beta of 1.96.

Wall Street Analysts Forecast Growth

CNTX has been the subject of several research reports. JonesTrading assumed coverage on Context Therapeutics in a research note on Monday, December 22nd. They set a “buy” rating and a $7.00 price target for the company. Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Wall Street Zen lowered shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Context Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in shares of Context Therapeutics during the 4th quarter valued at about $3,824,000. Marshall Wace LLP increased its position in shares of Context Therapeutics by 7,153.7% in the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after purchasing an additional 2,557,448 shares during the last quarter. Vanguard Group Inc. raised its stake in Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after purchasing an additional 134,449 shares in the last quarter. Renaissance Technologies LLC lifted its position in Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after purchasing an additional 188,202 shares during the last quarter. Finally, State Street Corp grew its stake in Context Therapeutics by 8.5% in the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after buying an additional 13,000 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.